Gene therapy retreatment aims to cut surgeries for rare throat tumor condition

NCT ID NCT06538480

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a gene therapy called Zopapogene imadenovec (Zopa) in 30 adults with recurrent respiratory papillomatosis (RRP), a condition causing non-cancerous throat tumors that often require repeated surgeries. One group will check how the virus used in the therapy leaves the body, while another group will see if retreatment can eliminate the need for surgery for a full year. The goal is to control the disease and reduce the burden of frequent procedures.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RECURRENT RESPIRATORY PAPILLOMATOSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

human papilloma virus infection recurrent respiratory papillomatosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • National Institute of Health

    RECRUITING

    Bethesda, Maryland, 20892, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • University of Cincinnati

    RECRUITING

    Cincinnati, Ohio, 45267, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Winship Cancer Institute, Emory University

    RECRUITING

    Atlanta, Georgia, 30322, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact